Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

• Published in: Frontiers in oncology Vol. 11; p. 641955
• Main Authors: Guan, Tianwang, Qiu, Zicong, Su, Miao, Yang, Jinming, Tang, Yongshi, Jiang, Yanting, Yao, Dunchen, Lai, Yanxian, Li, Yanfang, Liu, Cheng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 11.05.2021
• Subjects: cardio-oncology; cardiovascular death; chemotherapy; non-central nervous system lymphoma; Oncology; primary central nervous system lymphoma; SEER; SEER; cardiovascular death; cardio-oncology; chemotherapy; non-central nervous system lymphoma; primary central nervous system lymphoma
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.641955

To study the cardiovascular death (CVD) risk in primary central nervous system lymphoma (PCNSL) patients with chemotherapy. We obtained 2,020 PCNSL participants and 88,613 non-central nervous system lymphoma (NCNSL) participants with chemotherapy from Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015. A 1:3 propensity score matching (PSM) was used to reduce the imbalance between PCNSL participants with and without chemotherapy, as well as the imbalance between PCNSL and NCNSL participants with chemotherapy. Competing risks regressions were conducted to evaluate the independent influence of chemotherapy on CVD. After 1:3 PSM, the CVD risk in PCNSL patients with chemotherapy was lower than those without chemotherapy [decreased 53%, adjusted HR, 0.469 (95% CI, 0.255-0.862; = 0.015)] as well as NCNSL patients with chemotherapy [decreased 36%, adjusted HR in model 1, 0.636 (95% CI, 0.439-0.923; = 0.017)]. The CVD risk of chemotherapy decreased in PCNSL patients with age at diagnosis >60 years old [adjusted HR, 0.390 (95% CI, 0.200-0.760; = 0.006)], and those patients diagnosed at 2010 to 2015 [adjusted HR, 0.339 (95% CI, 0.118-0.970; = 0.044)]. PCNSL patients with chemotherapy are associated with lower CVD risk. Our findings may provide new foundations for that chemotherapy is the first-line treatment for PCNSL patients, according to a cardiovascular risk perspective.